Literature DB >> 12915631

Growth inhibition by glucocorticoid treatment in salt wasting 21-hydroxylase deficiency: in early infancy and (pre)puberty.

Nike M M L Stikkelbroeck1, Bep A E Van't Hof-Grootenboer, Ad R M M Hermus, Barto J Otten, Martin A Van't Hof.   

Abstract

In patients with congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency, adult height is below target height. This may result from growth inhibition by glucocorticoid treatment. Previous studies suggest that glucocorticoids have a dose-dependent negative effect on growth in CAH patients and that this effect is age dependent. This study analyzed the correlation between glucocorticoid dose and growth in these patients. A retrospective study was carried out on growth data from 48 patients with classic salt-wasting 21-hydroxylase deficiency who all had been diagnosed in the first year of life and treated from the moment of diagnosis with glucocorticoids and mineralocorticoids. Analysis of the effect of prescribed glucocorticoid dose on growth was performed in age intervals, by analysis of covariance (ANCOVA). The dependent variables height for age z-score (HAZ), weight for age z-score (WAZ) (both corrected for secular trend), and weight for height z-score (WHZ), at 10 selected ages (1, 2, 4, 6, 8, 10, 12, 14, 16, and 18 yr) were explained by 1) mean daily glucocorticoid dose per body surface in the preceding age interval; 2) HAZ, WAZ, or WHZ value at the beginning of the age interval; 3) HAZ, WAZ, or WHZ value 1 yr before the beginning of the considered age interval; and 4) midparental height (only for HAZ). ANCOVA showed that the daily glucocorticoid dose had significant negative effects on HAZ between the ages of 6 and 12 months and between the age of 8-10 and 12-14 yr (and a trend toward significance between 10-12 yr). The negative glucocorticoid effect on HAZ in the age interval of 12-14 yr was as large as in the interval between 6 and 12 months of age. Weight and weight for height were not significantly influenced by glucocorticoid dose in any of the age intervals. We conclude that in CAH patients in the first year of life and between the ages of 8 and 14 yr, there is a dose-dependent negative effect of glucocorticoids on linear growth. Therefore, the daily glucocorticoid dose in these periods should be sufficient to avoid androgen excess, but as low as possible to allow optimal linear growth and adult height.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12915631     DOI: 10.1210/jc.2002-030011

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  16 in total

Review 1.  Growth in congenital adrenal hyperplasia.

Authors:  An Tt Nguyen; Justin J Brown; Garry L Warne
Journal:  Indian J Pediatr       Date:  2006-01       Impact factor: 1.967

2.  Growth hormone response to physical exercise in growing patients with classic congenital adrenal hyperplasia.

Authors:  C Bizzarri; G Ubertini; F Crea; D Colabianchi; S Loche; L Ravà; M Cappa
Journal:  J Endocrinol Invest       Date:  2009-06-24       Impact factor: 4.256

3.  Growth Pattern and Clinical Profile of Indian Children with Classical 21-Hydroxylase Deficiency Congenital Adrenal Hyperplasia on Treatment.

Authors:  H Meena; Manisha Jana; Vishwajeet Singh; Madhulika Kabra; Vandana Jain
Journal:  Indian J Pediatr       Date:  2019-01-30       Impact factor: 1.967

Review 4.  Congenital adrenal hyperplasia: issues in diagnosis and treatment in children.

Authors:  Rajni Sharma; Anju Seth
Journal:  Indian J Pediatr       Date:  2013-11-20       Impact factor: 1.967

5.  Impact of availability of oral hydrocortisone on growth of children with CAH.

Authors:  V V Khadilkar; A V Khadilkar; G B Maskati
Journal:  Indian J Pediatr       Date:  2005-04       Impact factor: 1.967

6.  Comparison of multiple steroid concentrations in serum and dried blood spots throughout the day of patients with congenital adrenal hyperplasia.

Authors:  Kyriakie Sarafoglou; John H Himes; Jean M Lacey; Brian C Netzel; Ravinder J Singh; Dietrich Matern
Journal:  Horm Res Paediatr       Date:  2010-08-25       Impact factor: 2.852

Review 7.  Glucocorticoids and the regulation of growth hormone secretion.

Authors:  Gherardo Mazziotti; Andrea Giustina
Journal:  Nat Rev Endocrinol       Date:  2013-02-05       Impact factor: 43.330

8.  Growth and reproductive outcomes in congenital adrenal hyperplasia.

Authors:  Todd D Nebesio; Erica A Eugster
Journal:  Int J Pediatr Endocrinol       Date:  2010-02-01

9.  Bone health should be an important concern in the care of patients affected by 21 hydroxylase deficiency.

Authors:  Anne Bachelot; Zeina Chakhtoura; Dinane Samara-Boustani; Jérome Dulon; Philippe Touraine; Michel Polak
Journal:  Int J Pediatr Endocrinol       Date:  2010-09-28

10.  Motor development in individuals with congenital adrenal hyperplasia: strength, targeting, and fine motor skill.

Authors:  Marcia L Collaer; Charles G D Brook; Gerard S Conway; Peter C Hindmarsh; Melissa Hines
Journal:  Psychoneuroendocrinology       Date:  2008-10-19       Impact factor: 4.905

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.